SmartCella Holding AB
Johan Rugfelt is an experienced executive with a strong background in biotech, medtech, and management consulting. Currently serving as COO of SmartCella Holding AB since August 2019, Johan contributes to pioneering targeted therapies through innovative delivery platforms. Previously, as COO and Acting CEO at Bactiguard AB from April 2010 to June 2022, Johan oversaw operations including production, supply chain, and regulatory affairs. Johan's diverse experience includes leadership positions at the Swedish Trade Council, Bain & Company, SEB Merchant Banking, and Result, where expertise in international business expansion was developed. Johan holds a Master's degree in Business Administration and Management from the Stockholm School of Economics.
This person is not in any teams
SmartCella Holding AB
SmartCella, founded in 2014, is an innovative biotechnology company based in Stockholm, Sweden. SmartCella’s vision is to combine first-in-class delivery platforms with cutting-edge cell and gene therapies to unleash the full potential of targeted therapies. The company has three main business units, Smartwise, SmartCella Solutions and Procella. Smartwise is developing and manufacturing a first-in-class endovascular delivery device, the Extroducer, that enables direct tissue/organ infusions through the vessel wall directly into to hard-to-reach organs and tumors. There is a significant unmet need in the field of targeted delivery of different types of therapies for regeneration of tissue and for treatment of cancer tumors. Smartwise received regulatory approval from the US FDA for the Extroducer in June 2022 and is now actively out-licensing the technology to global companies with therapies that benefit from direct delivery. SmartCella Solutions create novel mRNA therapies and platforms that enable cell-mediated delivery of protein and mRNA to specific regions, even within organs or microenvironments. A pipeline of projects within regeneration and tolerization, focusing on oncology, is in pre-clinical development. Procella has advanced capabilities within stem cell therapy development and inhouse cGMP manufacturing of cell based therapies, with a proven platform to take stem cell projects from discovery phase to clinical development. A globally licensed cardiac stem cell therapy is entering clinical stages (in collaboration with AstraZeneca) and there is a growing pipeline of projects in different stages of development, with dopamine producing cells for Parkinson´s Disease and our own iMSCs most advanced.